It’s been more than two years since we reported on the appeal in the Darvocet MDL (In re: Darvocet, Darvon and Propoxyphene Products Liability Litigation, No. 11-md-2226-DCR, MDL 2226), which involves claims against generic manufacturers of a generic equivalent of the drug Darvon. The biggest news is that the panel did not decide whether to … Continue Reading
In Strayhorn v. Wyeth Pharms., Inc., decided this Monday, the Sixth Circuit affirmed the complete dismissal of claims against makers of generic drugs under the Supreme Court’s decisions in PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), and Mutual Pharmaceutical Co. v. Bartlett, 133 S. Ct. 2466 (2013). Judge Gilman’s opinion reads those cases as … Continue Reading
